Integrity | Ambition | Energy
Atturos was founded in 2014 as a spin out company from University College Dublin with the ambition to develop and commercialise advanced diagnostics solutions to enable clinicians and patients make better decisions. Leveraging extensive expertise in mass spectrometry, proteomics and clinical research, Atturos is focussed on clinical and commercial translation of our lead product, the OCProDx test. This novel multimarker test is being developed to address a significant unmet need in the treatment of prostate cancer. Supported in part by a prestigious EU Horizon 2020 SME Instrument award the Atturos Leadership Team are working closely with multiple stakeholders across the clinical, scientific, and business community to drive the rapid growth and development of the company. For a summary of our plans click here. The Atturos team are unashamedly ambitious in their plans for the company’s growth, however conscious that the result of the tests we are developing will influence the clinical decisions that change patients lives. We apply integrity to all we do in close association with patients and clinicians.